Amortization of intangible assets, excluding patents.

No definition available.

Name:	neos_AmortizationOfIntangibleAssetsExcludingPatents
Namespace Prefix:	neos_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Represents the fair value of estimated earnout costs.

+ References

No definition available.

+ Details

Name:	neos_EarnoutCostFairValue
Namespace Prefix:	neos_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Accumulated amortization of all finite-lived intangible assets, excluding goodwill and patents, as of the balance sheet date

+ References

No definition available.

+ Details

Name:	neos_FiniteLivedIntangibleAssetsExcludingGoodwillAndPatentsAccumulatedAmortization
Namespace Prefix:	neos_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount before amortization of all finite-lived intangible assets, excluding goodwill and patents, as of the balance sheet date.

+ References

No definition available.

+ Details

Name:	neos_FiniteLivedIntangibleAssetsGrossExcludingGoodwillAndPatents
Namespace Prefix:	neos_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Sum of the carrying amounts of all intangible assets, excluding goodwill and patents, as of the balance sheet date, net of accumulated amortization and impairment charges

+ References

No definition available.

+ Details

Name:	neos_IntangibleAssetsNetExcludingGoodwillAndPatents
Namespace Prefix:	neos_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Amount of legal fees capitalized and included in the purchase price during the period.

+ References

No definition available.

+ Details

Name:	neos_LegalFeesCapitalized
Namespace Prefix:	neos_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 50

-Paragraph 4

-Subparagraph (a)(1)

-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479

+ Details

Name:	us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

No definition available.

+ Details

Name:	us-gaap_FiniteLivedIntangibleAssetUsefulLife
Namespace Prefix:	us-gaap_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_FiniteLivedIntangibleAssetsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 3

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16373-109275

+ Details

Name:	us-gaap_ImpairmentOfIntangibleAssetsFinitelived
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3213-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

+ Details

Name:	us-gaap_PaymentsToAcquireIntangibleAssets
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=neos_ProprietaryModifiedReleaseDrugDeliveryTechnologyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=neos_RightsToTussionexAndaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=neos_CpiProfitSharingMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=neos_RightsToTussionexAndaAndCpiProfitSharingMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Intangible assets, net (Details) - USD ($)		3 Months Ended		6 Months Ended
Intangible assets, net (Details) - USD ($)	Aug. 28, 2014	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014
Intangible assets disclosures
Intangible assets, excluding patents, gross		$ 22,756,000		$ 22,756,000		$ 22,756,000
Accumulated amortization		(5,336,000)		(5,336,000)		(4,589,000)
Intangible assets, excluding patents, net		17,420,000		17,420,000		18,167,000
Amortization of Intangible Assets, Excluding Patents				747,000	$ 404,000
Proprietary modified-release drug delivery technology
Intangible assets disclosures
Intangible assets, excluding patents, gross		15,600,000		$ 15,600,000		15,600,000
Useful life				20 years
Amortization of Intangible Assets, Excluding Patents		195,000	$ 195,000	$ 390,000	390,000
Tussionex ANDA
Intangible assets disclosures
Intangible assets, excluding patents, gross		4,829,000		4,829,000		4,829,000
Payment made to acquire asset	$ 4,200,000
Legal fees	90,000
Earnout fair value	589,000
Decrease in the value because of reclassification from Schedule III to Schedule II				400,000
Tussionex ANDA \| Other income (expense)
Intangible assets disclosures
Increase (decrease) in fair value of earnout liability		42,000
CPI Profit Sharing
Intangible assets disclosures
Intangible assets, excluding patents, gross		2,043,000		2,043,000		2,043,000
Payment made to acquire asset	2,000,000
Legal fees	$ 43,000
Other
Intangible assets disclosures
Intangible assets, excluding patents, gross		284,000		284,000		$ 284,000
Tussionex ANDA and CPI profit sharing
Intangible assets disclosures
Useful life	10 years
Amortization of Intangible Assets, Excluding Patents		$ 171,000	$ 0	$ 343,000	$ 0